Hengrui Therapeutics Inc. (HTI), of Princeton, N.J., said it inked an agreement with Bio Holdings Ltd., a joint venture between China's Jiangsu Hengrui's Medicine Co. Ltd. and an undisclosed blue chip investment firm, regarding a $100 million investment in HTI. Proceeds will be used to advance clinical trials. HTI is a recently formed startup with a pipeline of clinical-stage oncology and immuno-oncology assets.